The global gastric cancer market is anticipated to grow at a modest CAGR of around 6.8% during the forecast period (2021-2027). The rising prevalence of gastric cancer and the growing geriatric population is the major factor driving the growth of the market. According to the American Cancer Society, stomach cancer accounts for about 1.5% of all new cancers diagnosed in the US each year. Stomach cancer mostly affects older people. The average age of people when they are diagnosed is 68. About 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. According to WHO, approx. 800,000 cancer-related death are caused by gastric cancer every year. Due to the increase in the number of gastric cancer cases, the demands for advanced and effective treatments increase, which positively affected the market growth. Additionally, the new combined therapies also proved best for the cancer treatments, such as when chemotherapy combined with radiation therapy gives better results.
Browse the full report description of "Global Gastric Cancer Market Size, Share & Trends Analysis Report by Testing Type (Chest X-Ray, Computed Tomography (CT OR CAT) Scan, Laparoscopy, MRI Scan, PET Scan, and Others) By Treatment Type (Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy, and Immunotherapy) By End-User (Hospitals & Clinics, Specialized Cancer Treatment Centers, and Others) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/gastric-cancer-market
The rising FDA approvals for cancer treatments drugs is the major factor that is expected to increase these drug demands and will offer various opportunities to manufacturers. For instance, in April 2021, the FDA approved Nivolumab in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. Moreover, in January 2021, the FDA approved Enhertu (trastuzumab deruxtecan) drug, produced by AstraZeneca and Daiichi Sankyo Co., Ltd, for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric cancer. Considering these FDA approvals, considerable growth can be expected in the global gastric cancer market during the forecast period.
Market Coverage
o By Testing Type
o By Treatment Type
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Gastric Cancer Market Report Segment
By Testing Type
By Treatment Type
By End-Users
Global Gastric Cancer Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/gastric-cancer-market